The combination of ipilimumab and nivolumab replaces the previous standard of care for the first-line treatment of patients with intermediate- and poor-risk metastatic clear-cell renal cancer, according to updated EAU guidelines.


The updated 2017 American Urological Association (AUA) guidelines for localized kidney cancer have been released, focusing on functional outcomes in relation to multiple treatment options.

Read More

The first evidence-based guidelines for the use of immunotherapies in the treatment of patients with renal cell carcinoma (RCC) have now been published by the Society for ImmunoTherapy of Cancer (SITC).

Read More

Research in Review

A look at 14 years of health care trends has revealed that the percentage of patients receiving treatment for metastatic renal cell carcinoma (mRCC) is growing as providers shift toward targeted therapeutic approaches. 

Read More

Subscribe to Kidney Cancer